The rollout is taking place in stages. The first new line for pre-sterilized syringes is already operational, and a second is scheduled to follow by the end of 2026. We are also planning five additional aseptic filling lines by 2028. We will install three more lines at our new commercial site in Saarlouis, where operations are expected to begin in 2031.
Investing in capacity and modern production
In addition to boosting our production capacity, we are also enhancing our operational infrastructure. We are investing in compounding, warehousing, and visual inspection, supported by advanced cleanroom technology and higher levels of automation and digitalization.
“Pharmaceutical and biotech companies are seeking partners with extensive experience and the operational know-how to support the production of their current and future medicines,” explains Managing Director Henryk Badack. “This need is reflected in our long-term growth strategy. Through continuous investments, we are expanding our global manufacturing capabilities to support customers throughout the entire lifecycle of their products.”
“Our phased approach allows us to add capacity while systematically expanding our global manufacturing network,” explains Managing Director Carsten Press. “These investments lay the foundation for scalable production processes, stable supply chains, and high-quality aseptic manufacturing. This is how we support our customers’ long-term growth.”
